Valuation: Alkem Laboratories Limited

Market Cap 631B 6.52B 5.82B 5.42B 4.93B 9.31B 9.35B 65.21B 25.55B 322B 24.49B 23.96B 1,033B P/E 2027 *
27.5x
P/E 2028 * 23.9x
Enterprise Value 618B 6.39B 5.7B 5.31B 4.83B 9.11B 9.15B 63.86B 25.02B 315B 23.98B 23.46B 1,011B EV / Sales 2027 *
3.7x
EV / Sales 2028 * 3.24x
Free-Float
38.59%
Yield 2027 *
0.95%
Yield 2028 * 1.05%
09-24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer CI
09-24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Key Managerial Personnel and Senior Management Personnel, Effective September 30, 2026 CI
09-16 Alkem Laboratories Limited Launches Neuceno for the Treatment of Partial-Onset Seizures in Adult Patients CI
09-15 Alkem Laboratories Limited Announces Appointment of Shubhadeep Sinha to Senior Management Position, Effective September 15, 2026 CI
09-08 Alkem Laboratories Limited Launches Renocia Exo, India?s First Patented Ginsenoside Exosome-Based Hair Growth Serum CI
08-14 Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026
08-14 Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-03 Alkem Laboratories Limited Announces Appointment of Rajpal Singh Rana to Senior Management Position, Effective August 03, 2026 CI
07-23 Alkem Laboratories Limited Announces Resignation of Resignation of Jitendra Singh Huda as Senior Management Personnel, Effective from July 23, 2026 CI
06-02 Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 CI
06-02 Alkem Laboratories Shows Strong Moves But Weak Follow-Through Zonebourse
05-29 Bob Capital Markets Downgrades Alkem Laboratories to Sell From Hold; Price Target is INR4,638 MT
05-29 Jefferies Adjusts Alkem Laboratories' Price Target to INR6,500 From INR6,550, Keeps at Buy MT
1 day-0.67%
1 week+0.98%
Current month+1.55%
1 month+1.60%
3 months-5.81%
6 months-2.26%
Current year-4.78%
1 week 5,165
Extreme 5165
5,407
1 month 5,110
Extreme 5110
5,466.5
Current year 5,051
Extreme 5051
5,933.5
1 year 5,051
Extreme 5051
5,933.5
3 years 3,509.95
Extreme 3509.95
6,439.9
5 years 2,828
Extreme 2828
6,439.9
10 years 1,455
Extreme 1455
6,439.9
Manager TitleAgeSince
President - -
President - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 44 09/08/2013
Director/Board Member 63 11/02/2008
Director/Board Member 45 11/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%+0.98%-4.53%+45.86% 6.52B
+0.83%+3.19%+41.49%+94.83% 1,051B
+1.93%+2.11%+37.08%+67.40% 630B
+1.49%+5.19%+19.94%+85.13% 489B
+2.26%+0.90%+69.32%+40.73% 359B
+0.28%+3.50%+23.29%+40.84% 344B
+0.34%+2.37%+13.47%+32.81% 272B
+0.33%+1.08%-6.13%+9.63% 246B
+1.82%+2.94%+42.99%+46.29% 224B
+2.77%+4.44%+29.01%+96.43% 187B
Average +1.14%+2.69%+26.59%+55.99% 381.02B
Weighted average by Cap. +1.27%+2.93%+33.29%+66.27%

Financials

2027 *2028 *
Net sales 167B 1.73B 1.54B 1.43B 1.3B 2.46B 2.47B 17.25B 6.76B 85.13B 6.48B 6.34B 273B 186B 1.92B 1.72B 1.6B 1.45B 2.74B 2.75B 19.22B 7.53B 94.83B 7.22B 7.06B 304B
Net income 23.1B 239M 213M 198M 180M 340M 342M 2.39B 935M 11.77B 896M 877M 37.79B 27.28B 282M 252M 234M 213M 402M 404M 2.82B 1.1B 13.91B 1.06B 1.04B 44.63B
Net Debt -13.12B -136M -121M -113M -102M -193M -194M -1.36B -531M -6.69B -509M -498M -21.47B -28.19B -291M -260M -242M -220M -416M -417M -2.91B -1.14B -14.37B -1.09B -1.07B -46.11B
Projected Income Statement - Annual - Alkem Laboratories Limited
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Employees
19,346
Date Price Change Volume
12/10/26 ₹5,243.50 -0.67% 122,936
09/10/26 ₹5,279.00 +0.56% 96,074
08/10/26 ₹5,249.50 -1.89% 281,234
07/10/26 ₹5,350.50 +1.11% 205,152
06/10/26 ₹5,292.00 +1.92% 63,668
Trader
Investor
Global
Quality
ESG MSCI
BB
Ratings Surperformance© - Alkem Laboratories Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5,279.00INR
Average target price
6,002.55INR
Spread / Average Target
+13.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alkem Laboratories Limited
  1. Stock Market
  2. Stocks
  3. ALKEM Stock